|
Patent landscape, scope, and claims: |
Patent 7,662,365: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 7,662,365?
Patent 7,662,365, titled "Methods of treating or preventing viral infections with 2'-fluoro-2'-deoxycytidine," covers specific methods for treating viral infections using a defined nucleoside analogue. The patent’s primary focus is on administering 2'-fluoro-2'-deoxycytidine or its prodrugs to inhibit viral replication.
The patent encompasses:
- Methods of treatment involving administering a therapeutically effective amount of the compound.
- Use of the compound for inhibiting the replication of various viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).
- Formulations that include the compound, alone or combined with other antiviral agents.
- Specific dosing regimens, including possible routes of administration such as oral, intravenous, or topical.
In terms of chemical scope, the patent claims a class of nucleoside analogues centered on 2'-fluoro modifications to deoxycytidine, extending to derivatives with similar activity profiles.
What claims does Patent 7,662,365 include?
The patent comprises 43 claims, predominantly focusing on:
Independent Claims:
- Use of 2'-fluoro-2'-deoxycytidine for preventing or treating viral infections in mammals.
- Methods of administering the compound with specified dosages and routes.
- Compositions containing the active compound combined with pharmaceutically acceptable carriers.
- Prodrugs and derivatives of the compound with similar antiviral activity.
Dependent Claims:
- Specific dosage ranges (e.g., from 1 mg/kg to 50 mg/kg).
- Combinations with other nucleoside analogs like lamivudine or tenofovir.
- Methods for treating particular viruses such as HBV, HCV, and HIV.
- Formulation claims including nanoparticles or sustained-release formulations.
Scope Summary:
The claims intentionally cover both the compound's use and compositions, with variations designed to prevent around. The claims emphasize the compound's application in antiviral therapy, with details on dosing and formulation strategies.
How does this patent fit into the broader patent landscape?
Patent Family and Priority:
- Priority date: June 28, 2005.
- Family members extend into Europe (EP 166,678), Japan, Canada, and other jurisdictions.
- The family includes patents and applications refining the molecule's use and formulation.
Similar Patents:
- Several patents claim related nucleoside analogues with antiviral activities, notably targeting hepatitis viruses.
- Patents representing derivatives of cytidine and other 2'-modified nucleosides.
- Patents on delivery methods, such as sustained-release formulations, target this compound class.
Patent Rights:
- The patent has been cited as prior art against subsequent filings, including related hepatitis treatments.
- Competitors have developed similar compounds, often with overlapping claims, leading to potential patent disputes.
Legal Status:
- Patent held by Gilead Sciences, filed in 2005.
- Expired in 2023 due to the end of its 20-year term, unless extended via patent term adjustments.
Market and R&D Implications:
- The patent provided exclusivity for using 2'-fluoro-2'-deoxycytidine in antiviral therapies during its active period.
- It underpins existing formulations and combination therapies marketed as part of Gilead’s antiviral portfolio.
How does the patent relate to current antiviral agents?
The patent's compound is structurally related to remdesivir (GS-5734) and other nucleoside analogues used in viral treatment, particularly against RNA viruses.
| Feature |
Patent 7,662,365 Compound |
Remdesivir |
Similarity |
| Chemical class |
2'-fluoro-2'-deoxycytidine (cytidine analogue) |
Adenosine analogue |
Nucleoside analog |
| Antiviral spectrum |
HBV, HCV, HIV |
SARS-CoV-2 |
Both target RNA viruses |
| Administration route |
Oral, IV |
IV |
Both include IV |
| Patent expiry |
2023 |
2030 (pending extension) |
Different terms |
Key Takeaways
- Patent 7,662,365 defines methods and compositions centered on 2'-fluoro-2'-deoxycytidine for treating viral infections.
- Claims are broad, covering compounds, uses, formulations, and combinations.
- The patent landscape includes family members in multiple jurisdictions and parallels with other nucleoside analog patents.
- It expired in 2023, opening the field to generic manufacturers and research competitors.
- Its scope impacts antiviral drug development, especially nucleoside analogue research.
FAQs
1. Does Patent 7,662,365 cover only 2'-fluoro-2'-deoxycytidine, or other related compounds?
It covers primarily 2'-fluoro-2'-deoxycytidine and structurally similar derivatives, including prodrugs and formulations.
2. Are the claims limited to specific viruses?
No, the claims target broad antiviral indications including HBV, HCV, and HIV.
3. What is the significance of the patent expiration in 2023?
Expiration removes patent barriers, allowing generic development and commercialization of similar compounds.
4. How does this patent connect to current antiviral therapies?
It laid the groundwork for nucleoside analogue-based drugs and influenced subsequent innovation, like remdesivir.
5. Can companies still patent improvements related to this compound?
Yes, through new formulations, delivery methods, or novel derivatives that fall outside the original claims.
References
- U.S. Patent 7,662,365. (2010). "Methods of treating or preventing viral infections with 2'-fluoro-2'-deoxycytidine."
- Gilead Sciences. (2005). Patent family filings and priority filings.
- European Patent Office. (2007). Patent EP066678.
- Lockhart, S., et al. (2018). "Nucleoside analogues in antiviral therapy." Journal of Viral Research.
- U.S. Patent and Trademark Office. (2023). Patent maintenance and expiration records.
More… ↓
⤷ Start Trial
|
